Additionally, it has been reported to work in conjunction with vascular endothelial growth factor receptors (VEGFR)‐2 and VEGFR‐3, influencing hepatic vascular development and potentially contributing to HCC onset in patients with chronic hepatitis C [25]. This evidence concerns the gene FLT4 and hepatocellular carcinoma.